

ANALYSIS OF THIOCTIC ACID DRUGS CONSUMPTION IN THE UKRAINIAN PHARMACEUTICAL MARKET

E.I. Hyzhka, O.N. Kyrychenko

The National University of Pharmacy, Kharkiv, Ukraine

feknfau@ukr.net

Introduction. In the treatment of diseases and pathological conditions, which are based on oxidation-antioxidant homeostasis imbalance drugs of thioctic (α -lipoic) acid widely used. Thioctic acid is the first-line treatment of pathogenic diseases that are accompanied by severe neurological symptoms (diabetic and alcoholic polyneuropathy), liver pathology and others. In particular, clinical efficacy and safety of α -lipoic acid in the treatment of diabetic polyneuropathy was confirmed in 9 placebo controlled trials and one meta-analysis.

The purpose of the study is the assessment of thioctic acid drugs consumption in the Ukrainian pharmaceutical market.

Materials and methods. The objective of the study was the data about thioctic acid consumption of a market research analytical system "Pharmstandard". Consumption of drugs was assessed using ATC/DDD methodology in term of DDD_s/1000 inhabitants/day (DDD_s/1000/d). This indicator gives an idea of the proportion of the population that receives certain drugs. Consumption of thioctic acid were performed according to the data 2008 - 2012.

Results. 25 thioctic acid trade names were represented in the Ukrainian pharmaceutical market in 2012.

Compared to the data in 2008, in 2012 the consumption of thioctic acid drugs in Ukraine increased by 1.49 times and as 3.36 DDD_s/1000/d. Consumption of the drugs "Berlithion" and "Dialipon" was the largest. Consumption of these drugs according to data in 2012 increased by 27.12% and 21.50% compared to data in 2008. In absolute terms the volume of consumption was defined at the level of 0.73 and 0.42 DDD_s/1000/d respectively. Consumption of the domestic drugs "Lipoic acid" in 2012 compared to data in 2008 decreased by 99.86%. Their share in absolute terms was 0,000012 DDD_s/1000/d. The leader in terms of consumption in 2012 was a drug "Berlithion 600" (Berlin-Chemie, Germany, 600 mg, amp. 24 ml, №5). Volume of consumption increased by 98.50% compared with 2008 in absolute terms was 0,2 DDD_s/1000/d.

Conclusions. The analysis of the consumption of thioctic acid drugs in terms DDD_s/1000/d in the pharmaceutical market of Ukraine determined growth of its level, about 1.5 times more compared with 2008. It indirectly reflects the growing disease accompanied by severe neurological symptoms.